These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3130316)

  • 21. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide in pediatric malignancies.
    Jürgens H; Treuner J; Winkler K; Göbel U
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):46-50. PubMed ID: 2649985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Homesley HD; Malfetano JH
    Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
    Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
    J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
    Li EX; Zhang YT; Shang JT; Xu Z; Geng Y; Li SM; Shi F; Wu YY
    Ai Zheng; 2006 Aug; 25(8):1048-51. PubMed ID: 16965692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of holoxan (iphosphamide) in malignant tumors].
    Perevodchikova NI; Orel NF; Trofimova NV
    Vopr Onkol; 1990; 36(9):1085-8. PubMed ID: 2122594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
    Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL; Brogden RN; Pilkington T; Faulds D
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours.
    Brühl P; Günther U; Hoefer-Janker H; Hüls W; Scheef W; Vahlensieck W
    Int J Clin Pharmacol Biopharm; 1976 Jul; 14(1):29-39. PubMed ID: 789266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Schnitker J; Brock N; Burkert H; Fichtner E
    Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
    Nobile MT; Rosso R; Brema F; Cinquegrana A; Santi L
    Tumori; 1984 Oct; 70(5):433-7. PubMed ID: 6438851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552.
    Case DC; Anderson J; Ervin TJ; Gottlieb A
    Hematol Oncol; 1991; 9(4-5):189-96. PubMed ID: 1743622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
    Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Scheulen ME; Niederle N; Bremer K; Schütte J; Seeber S
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
    Falkson G; Chasen MR; Falkson HC
    Invest New Drugs; 1990 May; 8(2):215-9. PubMed ID: 2166721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
    Case DC; Santarelli MT; Carey RW; Anderson J; Gottlieb A
    Med Pediatr Oncol; 1992; 20(4):325-9. PubMed ID: 1608355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.